Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients

Samiksha Ghimire, Bhagwan Maharjan, Erwin M. Jongedijk, Jos G.W. Kosterink, Gokarna R. Ghimire, Daan J. Touw, Tjip S. van der Werf, Bhabana Shrestha, Jan-Willem C. Alffenaar

Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018
Journal Issue: April
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Samiksha Ghimire, Bhagwan Maharjan, Erwin M. Jongedijk, Jos G.W. Kosterink, Gokarna R. Ghimire, Daan J. Touw, Tjip S. van der Werf, Bhabana Shrestha, Jan-Willem C. Alffenaar. Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients. Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis
Source: Eur Respir J 2016; 47: 1229-1234
Year: 2016



Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016
Year: 2017


Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis
Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance
Year: 2009


Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016
Year: 2017


A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis
Source: Eur Respir J 2009; 33: 387-393
Year: 2009



Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB)
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Source: Eur Respir J 2013; 42: 1614-1621
Year: 2013



Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
Source: Eur Respir J 2011; 38: 888-894
Year: 2011



Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
Source: Eur Respir J, 54 (5) 1901806; 10.1183/13993003.01806-2019
Year: 2019



Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
Source: Eur Respir J, 54 (5) 1901508; 10.1183/13993003.01508-2019
Year: 2019



Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Source: Eur Respir J 2012; 40: 1430-1442
Year: 2012



Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study
Source: Eur Respir J 2015; 46: 1205-1207
Year: 2015


Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
Source: Eur Respir J 2011; 38: 730-733
Year: 2011


Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China
Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020
Year: 2021



A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 722s
Year: 2004

Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012

Effect of fluoroquinolones on microbiologic outcome and survival in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 380s
Year: 2006

The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis
Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences
Year: 2012


Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience
Source: Eur Respir J 2016; 47: 333-336
Year: 2016